Mansour Ahmad M, Arevalo J Fernando, Ziemssen Focke, Mehio-Sibai Abla, Mackensen Friederike, Adan Alfredo, Chan Wai-Man, Ness Thomas, Banker Alay S, Dodwell David, Chau Tran Thi Ha, Fardeau Christine, Lehoang Phuc, Mahendradas Padmamalini, Berrocal Maria, Tabbarah Zuheir, Hrisomalos Nicholas, Hrisomalos Frank, Al-Salem Khalil, Guthoff Rainer
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; Rafic Hariri University Hospital, Beirut, Lebanon.
Am J Ophthalmol. 2009 Aug;148(2):310-316.e2. doi: 10.1016/j.ajo.2009.03.023. Epub 2009 May 9.
To assess the long-term role of bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) in inflammatory ocular neovascularization.
Retrospective multicenter consecutive case series of inflammatory ocular neovascularization.
settings: Multicenter institutional and private practices.
Patients with inflammatory ocular neovascularization in one or both eyes of varying etiologies who failed standard therapy. intervention: Intravitreal injection of bevacizumab.
Improvement of best-corrected visual acuity (BCVA) expressed as logarithm of minimal angle of resolution (logMAR), and decrease in central foveal thickness as measured by optical coherence tomography at 6, 12, 18, and 24 months of follow-up.
Mean logMAR BCVA (central foveal thickness) following intravitreal bevacizumab was as follows: baseline, 0.65 (6/27 or 20/90) (338 microm; 99 eyes of 96 patients); 6 months, 0.42 (6/16 or 20/53) (239 microm; 2.0 injections; 81 eyes); 12 months, 0.39 (6/15 or 20/49) (241 microm; 2.3 injections; 95 eyes); 18 months, 0.40 (6/15 or 20/50) (261 microm; 3.0 injections; 46 eyes); and 24 months, 0.34 (6/13 or 20/44) (265 microm; 3.6 injections; 27 eyes). Paired comparisons revealed significant visual improvement at 6 months of 2.4 lines (P = .000), at 12 months of 2.5 lines (P = .000), at 18 months of 2.5 lines (P = .001), and at 24 months of 2.2 lines (P = .013). Paired comparisons revealed significant central foveal flattening at 6 months of 78 microm (P = .000), at 12 months of 85 microm (P = .000), at 18 months of 90 microm (P = .003), and at 24 months of 77 microm (P = .022). Three eyes developed submacular fibrosis and 1 eye submacular hemorrhage.
Intravitreal bevacizumab led in the long-term to significant mean visual improvement of > or =2.2 lines and significant foveal flattening in a wide variety of inflammatory ocular diseases without major complications.
评估贝伐单抗（阿瓦斯汀；基因泰克公司，美国加利福尼亚州南旧金山）在炎症性眼部新生血管形成中的长期作用。
炎症性眼部新生血管形成的回顾性多中心连续病例系列研究。
地点：多中心机构及私人诊所。
病因各异的单眼或双眼炎症性眼部新生血管形成且标准治疗失败的患者。干预措施：玻璃体内注射贝伐单抗。
最佳矫正视力（BCVA）改善情况，以最小分辨角对数（logMAR）表示；以及在随访6、12、18和24个月时通过光学相干断层扫描测量的中心凹厚度降低情况。
玻璃体内注射贝伐单抗后的平均logMAR BCVA（中心凹厚度）如下：基线时，0.65（6/27或20/90）（338微米；96例患者的99只眼）；6个月时，0.42（6/16或20/53）（239微米；2.0次注射；81只眼）；12个月时，0.39（6/15或20/49）（241微米；2.3次注射；95只眼）；18个月时，0.40（6/15或20/50）（261微米；3.0次注射；46只眼）；24个月时，0.34（6/13或20/44）（265微米；3.6次注射；27只眼）。配对比较显示，6个月时视力显著改善2.4行（P = 0.000），12个月时改善2.5行（P = 0.000），18个月时改善2.5行（P = 0.001），24个月时改善2.2行（P = 0.013）。配对比较显示，6个月时中心凹显著变平78微米（P = 0.000），12个月时变平85微米（P = 0.000），18个月时变平90微米（P = 0.003），24个月时变平77微米（P = 0.022）。3只眼发生黄斑下纤维化，1只眼发生黄斑下出血。
玻璃体内注射贝伐单抗长期可使多种炎症性眼部疾病的平均视力显著改善≥2.2行，并使黄斑显著变平，且无重大并发症。
